Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes

Monzr Al Malki, MD, Sanjeet Dadwal, MD, Dongyun Yang, PhD, Sally Mokhtari, PhD, Thai Cao, MD, Ketevan Gendzekhadze, David S Snyder, MD, Haris Ali, MD, Ibrahim Aldoss, MD, Amandeep Salhotra, MD, Guido Marcucci, Chatchada Karanes, Pablo Parker, MD, Auayporn P. Nademanee, MDBS, Don Diamond, PhD, John Zaia, MD, Stephen J Forman, Ryotaro Nakamura, MD

Blood (2018) 132 (Supplement 1): 3416.

https://doi.org/10.1182/blood-2018-99-113514

Published: 2018

Journal Articles

Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation

Blood (2018) 132 (Supplement 1): 2181.

https://doi.org/10.1182/blood-2018-99-115467

Published: 2018

Journal Articles

A Phase II Study of Total Marrow and Lymphoid Irradiation (TMLI) in Combination with Cyclophosphamide and Etoposide in Patients with Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Blood (2017) 130 (Supplement 1): 4607.

https://doi.org/10.1182/blood.V130.Suppl_1.4607.4607

Published: 2017

Journal Articles

Ruxolinitib As Salvage Therapy for Chronic Graft-Versus-Host Disease

Badri Modi, MD, Michael Hernandez-Henderson, B.A., Erin Kopp, Dongyun Yang, PhD, Karen Huelsman, R.N., Pietro Sollena, MD, Jasmine M. Zain, MD, Haris Ali, MD, Monzr M. Al Malki, MD, Ricardo Spielberger, MD, Sanjeet Dadwal, MD, Amandeep Salhotra, MD, Stephen J. Forman, MD FACP, Pablo Parker, MD, Ryotaro Nakamura, MD

Blood (2017) 130 (Supplement 1): 1976.

https://doi.org/10.1182/blood.V130.Suppl_1.1976.1976

Published: 2017

Journal Articles

High Incidence of CMV Reactivation after Haploidentical Donor Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide, and Its Impact on Transplant Outcomes

Monzr M. Al Malki, MD, Sanjeet Dadwal, MD, Dongyun Yang, PhD, Sally Mokhtari, PhD, Thai Cao, MD, Ketevan Gendzekhadze, PhD, Ibrahim Aldoss, MD, Pablo Parker, MD, Margaret R. O'Donnell, MD, David S. Snyder, MD, David Senitzer, PhD, Joseph Rosenthal, MD MS, Auayporn P. Nademanee, MDBS, Don Diamond, PhD, John Zaia, MD, Stephen J. Forman, MD FACP, Ryotaro Nakamura, MD

Blood (2017) 130 (Supplement 1): 4494.

https://doi.org/10.1182/blood.V130.Suppl_1.4494.4494

Published: 2017

Journal Articles

Melphalan-Based Regimen Is a Safe and Effective Conditioning Regimen Prior to Allogeneic Hematopoietic Cell Transplantation in Older Adults (≥70 years) with Hematological Malignancies

Blood (2017) 130 (Supplement 1): 1995.

https://doi.org/10.1182/blood.V130.Suppl_1.1995.1995

Published: 2017

Journal Articles

Transfusion- Related Iron Overload (TRIO) Is Associated with Delayed Engraftment and Increased Non Relapse Mortality (NRM) in Patients Undergoing Umbilical Cord Blood (UCB) Hematopoietic Cell Transplantation (HCT)

Monzr M. Al Malki, MD, Joo Y. Song, MD, Dongyun Yang, PhD, Thai Cao, MD, Ibrahim Aldoss, MD, Sally Mokhtari, PhD, Sanjeet Dadwal, MD, Ketevan Gendzekhadze, PhD, Anna B Pawlowska, MD, Maryam Ameri, MD, Guido Marcucci, MD, Chatchada Karanes, Pablo Parker, MD, David S. Snyder, MD, David Senitzer, PhD, Auayporn P. Nademanee, MDBS, Stephen J. Forman, MD FACP, Ryotaro Nakamura, MD, Vinod Pullarkat, MD MRCP

Blood (2017) 130 (Supplement 1): 3212.

https://doi.org/10.1182/blood.V130.Suppl_1.3212.3212

Published: 2017

Journal Articles

Mycophenolate Mofitil (MMF) As Salvage Graft-Versus-Host Diseases (GVHD) Prophylaxis In Allogeneic Hematopoietic Stem Cell Transplantation (HCT) After Early Discontinuation Of Tacrolimus and/Or Sirolimus Due To Toxicities

Haris Ali, MD, Joycelynne Palmer, PhD, Zeynep Eroglu, MD, Tracey Stiller, Sandra H. Thomas, PhD, Samer Khaled, MBBCH, MD, Sepideh Shayani, Pharm.D., Pablo Parker, MD, Stephen J. Forman, MD, Ryotaro Nakamura, MD

Blood (2013) 122 (21): 5478.

https://doi.org/10.1182/blood.V122.21.5478.5478

Published: 2013

Journal Articles

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

George Somlo, MD, Paul Frankel, PhD, Ricardo Spielberger, MD, Chatchada Karanes, MD, Amrita Krishnan, MD, Pablo Parker, MD, Leslie Popplewell, MD, Firoozeh Sahebi, MD, Timothy Schultheiss, PhD, Neil Martin Kogut, MD, David S. Snyder, MD, Anthony Selwyn Stein, M.D., Stephen J. Forman, MD, Jeffrey Wong, MD

Blood (2012) 120 (21): 3151.

https://doi.org/10.1182/blood.V120.21.3151.3151

Published: 2012

Journal Articles

Phase I Trial of Escalated Doses of Targeted Marrow Radiation Delivered by Tomotherapy Combined with Etoposide and Cyclophosphamide; An Allogeneic HCT Preparative Regimen for Patients with Advanced Leukemia

Anthony Selwyn Stein, MD, Jeffrey Wong, MD, Joycelynne Palmer, PhD, Margaret O'Donnell, MD, David S. Snyder, MD, Ni-Chun Tsai, MS MPH, Pablo Parker, MD, Len Farol, MD, Ricardo Spielberger, MD, Firoozeh Sahebi, MD, Neil Kogut, MD, Joyce Murata-Collins, PhD, David Senitzer, PhD, Stephen J. Forman, MD

Blood (2012) 120 (21): 218.

https://doi.org/10.1182/blood.V120.21.218.218

Published: 2012

Journal Articles

Costimulatory Molecule Profiles After Autologous Hematopoietic Cell Transplantation (HCT) in Multiple Myeloma (MM) Patients

Myo Htut, MD, Ghislaine Gallez-Hawkins, Joycelynne Palmer, PhD, Xueli Liu, R. Spielberger, M.D., Pablo Parker, M.D., Len Farol, MD, Anne Franck, Xiuli Li, Jeannet Laëtitia, Eunicia Reburiano, Valerie Jimenez, Lupe Duarte, CCRC, Chatchada Karanes, MD, Stephen J. Forman, MD, John Zaia, MD, Amrita Krishnan, MD

Blood (2011) 118 (21): 5108.

https://doi.org/10.1182/blood.V118.21.5108.5108

Published: 2011

Journal Articles

Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era

Lester A. Laddaran, B.A., Can-Lan Sun, Ph.D., Ari M. VanderWalde, MD, MPH, Liton Francisco, B.S., Saro Armenian, D.O., M.P.H., Jennifer Berano Teh, M.D., F. Lennie Wong, Ph.D., Chatchada Karanes, MD, Neil Martin Kogut, MD, Amrita Krishnan, M.D., Auayporn Nademanee, M.D., Margaret O'Donnell, M.D., F.R.C.P.C., Pablo Parker, M.D., Leslie Popplewell, M.D., Anthony Selwyn Stein, M.D., Stephen J. Forman, M.D., Smita Bhatia

Blood (2010) 116 (21): 902.

https://doi.org/10.1182/blood.V116.21.902.902

Published: 2010

Journal Articles

Analysis of Risk Factors and Outcome for Extramedullary Relapses Post Allogeneic Stem Cell Transplantation for Myeloma.

Myo Htut, MD, Firoozeh Sahebi, M.D., George Somlo, MD, Pablo Parker, M.D., Chatchada Karanes, MD, Andy Dagis, Susan Hmwe, Tanya Paris, Joyce Murata-Collins, PhD, Leslie Popplewell, M.D., Joycelynne Palmer, PhD., Stephen Forman, M.D., Amrita Krishnan, M.D.

Blood (2010) 116 (21): 4562.

https://doi.org/10.1182/blood.V116.21.4562.4562

Published: 2010

Journal Articles

Response: A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 different conditioning regimens

Ryotaro Nakamura, Roberto Rodriguez, Sepideh Shayani, Pablo Parker, Stephen J. Forman

Blood (2010) 115 (21): 4317.

https://doi.org/10.1182/blood-2010-02-267260

Published: 2010

Journal Articles

A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens

Roberto Rodriguez, Ryotaro Nakamura, Joycelynne M. Palmer, Pablo Parker, Sepideh Shayani, Auyaporn Nademanee, David Snyder, Vinod Pullarkat, Neil Kogut, Joseph Rosenthal, Eileen Smith, Chatchada Karanes, Margaret O'Donnell, Amrita Y. Krishnan, David Senitzer, Stephen J. Forman

Blood (2010) 115 (5): 1098–1105.

https://doi.org/10.1182/blood-2009-03-207563

Published: 2010

Journal Articles

Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RI-HCT) for Myelodysplastic Syndrome (MDS) Using Tacrolimus/Sirolimus-Based Gvhd Prophylaxis.

Ryotaro Nakamura, MD, Joycelynne Palmer, Pablo Parker, Anthony Stein, Tracey Stiller, Vinod Pullarkat, David S. Snyder, MD, Ji-Lian Cai, MD, PhD, Shirong Wang, MD, MPH, David Senitzer, PhD, Karen L. Chang, Ravi Bhatia, Stephen J Forman, MD, Margaret O'Donnell, MD

Blood (2009) 114 (22): 2771.

https://doi.org/10.1182/blood.V114.22.2771.2771

Published: 2009

Journal Articles

Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma.

Mark Kirschbaum, MD, Maria Delioukina, Leslie Popplewell, MD, David S. Snyder, MD, Pablo Parker, Robert Chen, MD, Jasmine Zain, MD, Deron Matsuoka, Nony Obadike, Paul Frankel, Auayporn P. Nademanee, MD, Stephen J Forman, MD

Blood (2009) 114 (22): 1682.

https://doi.org/10.1182/blood.V114.22.1682.1682

Published: 2009

Journal Articles

Adding Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy to Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) in Patients (pts) with Advanced Hematological Malignancies.

Joseph Rosenthal, Jeffrey Y. Wong, George Somlo, David Snyder, Margaret O’Donnell, Anthony Stein, Ayurporn Nademanee, Maria Delioukina, Leslie Popplewell, Pablo Parker, Ricardo Spielberger, Firoozeh Sahebi, Chatchada Karanes, Debbie Hitt, Hossameldin Naeem, Andrew Dagis, Stephen Forman

Blood (2008) 112 (11): 3271.

https://doi.org/10.1182/blood.V112.11.3271.3271

Published: 2008

Journal Articles

Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study

Christopher J. Fraser, Smita Bhatia, Kirsten Ness, Andrea Carter, Liton Francisco, Mukta Arora, Pablo Parker, Stephen Forman, Daniel Weisdorf, James G. Gurney, K. Scott Baker

Blood (2006) 108 (8): 2867–2873.

https://doi.org/10.1182/blood-2006-02-003954

Published: 2006

Journal Articles

Transplant CD34+ Cell Dose Affects Outcomes Following Allogeneic Peripheral Blood Stem Cell Transplantation from a Matched Unrelated Donor.

Ryotaro Nakamura, MD, Joycelynne Palmer, PhD, Roberto Rodriguez, MD, Pablo Parker, MD, David Senitzer, PhD, Anthony Stein, MD, Josheph Rosenthal, MD, Sean Wang, MD, Jeffrey Schriber, MD, Stephen J. Forman, MD, Auayporn Nademanee, MD

Blood (2005) 106 (11): 2056.

https://doi.org/10.1182/blood.V106.11.2056.2056

Published: 2005

NARROW

Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes

Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation

A Phase II Study of Total Marrow and Lymphoid Irradiation (TMLI) in Combination with Cyclophosphamide and Etoposide in Patients with Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Ruxolinitib As Salvage Therapy for Chronic Graft-Versus-Host Disease

High Incidence of CMV Reactivation after Haploidentical Donor Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide, and Its Impact on Transplant Outcomes

Melphalan-Based Regimen Is a Safe and Effective Conditioning Regimen Prior to Allogeneic Hematopoietic Cell Transplantation in Older Adults (≥70 years) with Hematological Malignancies

Transfusion- Related Iron Overload (TRIO) Is Associated with Delayed Engraftment and Increased Non Relapse Mortality (NRM) in Patients Undergoing Umbilical Cord Blood (UCB) Hematopoietic Cell Transplantation (HCT)

Mycophenolate Mofitil (MMF) As Salvage Graft-Versus-Host Diseases (GVHD) Prophylaxis In Allogeneic Hematopoietic Stem Cell Transplantation (HCT) After Early Discontinuation Of Tacrolimus and/Or Sirolimus Due To Toxicities

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

Phase I Trial of Escalated Doses of Targeted Marrow Radiation Delivered by Tomotherapy Combined with Etoposide and Cyclophosphamide; An Allogeneic HCT Preparative Regimen for Patients with Advanced Leukemia

Costimulatory Molecule Profiles After Autologous Hematopoietic Cell Transplantation (HCT) in Multiple Myeloma (MM) Patients

Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era

Analysis of Risk Factors and Outcome for Extramedullary Relapses Post Allogeneic Stem Cell Transplantation for Myeloma.

Response: A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 different conditioning regimens

A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens

Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RI-HCT) for Myelodysplastic Syndrome (MDS) Using Tacrolimus/Sirolimus-Based Gvhd Prophylaxis.

Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma.

Adding Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy to Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) in Patients (pts) with Advanced Hematological Malignancies.

Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study

Transplant CD34+ Cell Dose Affects Outcomes Following Allogeneic Peripheral Blood Stem Cell Transplantation from a Matched Unrelated Donor.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only